Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-26-00672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Marla Lipsyc-Sharf und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Over the past three decades, the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone a remarkable transformation. Once associated with poor outcomes and a median survival of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, Los Angeles, Los Angeles, CA.
- Fred Hutchinson Cancer Center, Seattle, WA.
ORCID-Profile: Marla Lipsyc-Sharf, Sara A Hurvitz
Zitieren
APA
Lipsyc-Sharf, M., & Hurvitz, S. A. (2026). Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00672
Vancouver
Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00672
BibTeX
@article{LipsycSharf2026,
author = {Lipsyc-Sharf, Marla and Hurvitz, Sara A},
title = {Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00672}
}
EUVIMED